Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech

Executive Summary

Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.

Advertisement

Related Content

Vonoprazan Provides Foundation For Newly Minted Phathom
Troubled Realm Therapeutics Selling Assets, Delisting From London AIM
Biotech Showcase 2019: Fungal Platform Could Transform Biologics Manufacturing Costs
Realm Reaches End of The Road And Seeks Buyer
Adaptimmune Extends Funding Runway Ahead Of Clinical Results In Second Half
Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance
ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps
Visterra-Serum Combine Forces For Dengue Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125248

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel